Dutasteride/Tamsulosin In Benign Prostatic Hyperplasia

被引:7
作者
Keating, Gillian M. [1 ]
机构
[1] Adis, Auckland 0754, New Zealand
关键词
URINARY-TRACT SYMPTOMS; QUALITY-OF-LIFE; COMBINATION THERAPY; ENLARGED PROSTATE; 5-ALPHA-REDUCTASE INHIBITORS; TAMSULOSIN HYDROCHLORIDE; TREATMENT SATISFACTION; COST-EFFECTIVENESS; CLINICAL-OUTCOMES; PLUS TAMSULOSIN;
D O I
10.2165/11208920-000000000-00000
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The 5 alpha-reductase inhibitor dutasteride and the alpha(1)-adrenergic receptor antagonist tamsulosin are available as a fixed-dose combination for use in men with symptomatic benign prostatic hyperplasia (BPH) and an enlarged prostate. Dutasteride 0.5 mg/day plus tamsulosin 0.4 mg/day improved lower urinary tract symptoms (LUTS) to a significantly greater extent than dutasteride or tamsulosin alone in men with BPH, moderate to severe LUTS and an increased risk of disease progression, according to the results of the randomized, double-blind, multinational CombAT trial. The mean change from baseline in the total International Prostate Symptom Score was significantly greater with dutasteride plus tamsulosin than with dutasteride or tamsulosin alone after 2 years (primary endpoint) and 4 years of therapy. After 4 years' therapy in the CombAT trial, the time to first acute urinary retention or BPH-related surgery (primary endpoint) significantly favoured men with symptomatic BPH who were receiving dutasteride plus tamsulosin versus those receiving tamsulosin alone, with no significant difference between recipients of dutasteride plus tamsulosin and recipients of dutasteride alone. In the CombAT trial, health-related quality of life and treatment satisfaction were improved to a significantly greater extent with dutasteride plus tamsulosin than with dutasteride or tamsulosin alone. Combination therapy with oral dutasteride plus tamsulosin was generally well tolerated in patients with symptomatic BPH in the CombAT trial.
引用
收藏
页码:405 / 419
页数:15
相关论文
共 48 条
[1]   The Effect of Dutasteride on the Usefulness of Prostate Specific Antigen for the Diagnosis of High Grade and Clinically Relevant Prostate Cancer in Men With a Previous Negative Biopsy: Results From the REDUCE Study [J].
Andriole, Gerald L. ;
Bostwick, David ;
Brawley, Otis W. ;
Gomella, Leonard ;
Marberger, Michael ;
Montorsi, Francesco ;
Pettaway, Curtis ;
Tammela, Teuvo L. J. ;
Teloken, Claudio ;
Tindall, Donald ;
Freedland, Stephen J. ;
Somerville, Matthew C. ;
Wilson, Timothy H. ;
Fowler, Ivy ;
Castro, Ramiro ;
Rittmaster, Roger S. .
JOURNAL OF UROLOGY, 2011, 185 (01) :126-131
[2]   Effect of Dutasteride on the Risk of Prostate Cancer. [J].
Andriole, Gerald L. ;
Bostwick, David G. ;
Brawley, Otis W. ;
Gomella, Leonard G. ;
Marberger, Michael ;
Montorsi, Francesco ;
Pettaway, Curtis A. ;
Tammela, Teuvo L. ;
Teloken, Claudio ;
Tindall, Donald J. ;
Somerville, Matthew C. ;
Wilson, Timothy H. ;
Fowler, Ivy L. ;
Rittmaster, Roger S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (13) :1192-1202
[3]  
[Anonymous], LOW UR TRACT SYMPT M
[4]  
Antoñanzas F, 2011, ACTAS UROL ESP, V35, P65, DOI [10.1016/j.acuro.2010.11.008, 10.1016/S2173-5786(11)70020-8]
[5]   Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability [J].
Barkin, Jack .
PATIENT PREFERENCE AND ADHERENCE, 2011, 5 :483-490
[6]   Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial [J].
Barkin, Jack ;
Roehrborn, Claus G. ;
Siami, Paul ;
Haillot, Olivier ;
Morrill, Betsy ;
Black, Libby ;
Montorsi, Francesco .
BJU INTERNATIONAL, 2009, 103 (07) :919-926
[7]   The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study [J].
Becher, E. ;
Roehrborn, C. G. ;
Siami, P. ;
Gagnier, R. P. ;
Wilson, T. H. ;
Montorsi, F. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2009, 12 (04) :369-374
[8]   Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH [J].
Chung, B-H ;
Roehrborn, C. G. ;
Siami, P. ;
Major-Walker, K. ;
Morrill, B. B. ;
Wilson, T. H. ;
Montorsi, F. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2009, 12 (02) :152-159
[9]  
Clark R., 2005, European Urology Supplements, V4, P212, DOI 10.1016/S1569-9056(05)80844-9
[10]   Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor [J].
Clark, RV ;
Hermann, DJ ;
Cunningham, GR ;
Wilson, TH ;
Morrill, BB ;
Hobbs, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2179-2184